November 16, 2018
GCA Advises Cheplapharm on Its €300M Incremental TLB Facility Raise
GCA acted as exclusive debt advisor to Cheplapharm Arzneimittel GmbH on its successful increase of the syndicated and rated TLB facilities.
Cheplapharm is a family-owned pharmaceutical company that offers branded off-patent specialty products. The group has an international footprint and a broad portfolio of over 80 products across more than 10 therapeutic areas. Cheplapharm focuses on acquiring original, well-established, off-patent niche and legacy branded pharmaceuticals from large pharmaceutical companies, creating value through its global footprint.
In the summer of 2018, GCA advised Cheplapharm on its debut on the syndicated and rated TLB market. Following several acquisitions throughout 2018, which resulted in Cheplapharm’s growth, the TLB facilities were increased by €300M to provide liquidity for further M&A projects.
Sebastian F. Braun, CEO of Cheplapharm commented: "With the acquisition of five products in August and September, we are continuing our growth path and envisage to sign one more deal this year. The incremental facility provides us with the necessary liquidity.”